Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.64 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.50 |
| ▸ | TYR | P14679 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | GHSR | Q92847 | 2/20 | 0.47 |
| ▸ | ESR1 | P03372 | 3/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL827433 | 0.86 | RAB9A (0.54) | ALDH1A1HSD17B10KDM4EHPGDENPP2 | |
| Hydrochloric Acid SCHEMBL19211742 | 0.85 | RAB9A (0.53) | ALDH1A1HSD17B10KDM4EHPGDENPP2 | |
| SCHEMBL30440183 | 0.84 | ALDH1A1 (0.57) | ALDH1A1HSD17B10KDM4EHPGDENPP2 | |
| SCHEMBL217685 | 0.84 | ALDH1A1 (0.57) | ALDH1A1HSD17B10KDM4EHPGDENPP2 | |
| SCHEMBL30954329 | 0.83 | ALDH1A1 (0.60) | ALDH1A1HSD17B10KDM4EHPGDENPP2 | |
| SCHEMBL5484862 | 0.82 | OPRM1 (0.60) | ALDH1A1HSD17B10KDM4EHPGDENPP2 | |
| SCHEMBL7884484 | 0.82 | ALDH1A1 (0.54) | ALDH1A1HSD17B10KDM4EHPGDENPP2 | |
| Hydrochloric Acid SCHEMBL7885091 | 0.81 | ALDH1A1 (0.53) | ALDH1A1HSD17B10KDM4EHPGDENPP2 | |
| SCHEMBL121922 | 0.80 | ALDH1A1 (0.70) | ALDH1A1HSD17B10KDM4EHPGDENPP2 | |
| SCHEMBL2926458 | 0.79 | POLB (0.55) | ALDH1A1HSD17B10KDM4EHPGDENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118318033-A | Cell aggregate comprising pituitary hormone-producing cells and method for producing the same | 住友制药株式会社 | 2024-07-09 | — | — | CN | disclosed |
| CN-118043447-A | Method for preparing cell population containing pituitary tissue and cell population | 住友化学株式会社 | 2024-05-14 | — | — | CN | disclosed |
| CN-115650985-A | Heterocyclic compounds as RET kinase inhibitors | 癌症研究科技有限公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-109195972-B | Heterocyclic compounds as RET kinase inhibitors | 癌症研究科技有限公司 | 2022-10-28 | — | — | CN | disclosed |
| US-10954241-B2 | Heterocyclic compounds as ret kinase inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-03-23 | — | — | US | disclosed |
| US-10844067-B2 | Heterocyclic compounds as RET kinase inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2020-11-24 | — | — | US | disclosed |
| EP-3252050-B1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-02-26 | — | — | EP | disclosed |
| EP-3252050-B1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-02-26 | — | — | EP | disclosed |
| US-20190263819-A1 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-08-29 | — | — | US | disclosed |
| US-10385026-B2 | Phthalazinones and isoquinolinones as rock inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-08-20 | — | — | US | disclosed |
| US-20100010224-A1 | PROCESS FOR PRODUCTION OF HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST | MITSUBISHI RAYON CO., LTD. (JP) | 2010-01-14 | — | — | US | disclosed |
| US-7612218-B2 | Process for production of heteroaryl-type boron compounds with iridium catalyst | MITSUBISHI RAYON CO., LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20090215828-A1 | Substituted indole derivatives | GRUNENTHAL GMBH (DE) | 2009-08-27 | — | — | US | disclosed |
| EP-1948639-A2 | NOVEL CARBOCYCLIC FUSED CYCLIC AMINES | F. Hoffmann-la Roche AG (CH) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007054453-A2 | CARBOCYCLIC FUSED CYCLIC AMINES AS INHIBITORS OF THE COAGULATION FACTOR XA | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-18 | — | — | WO | disclosed |
| US-20060223826-A1 | Indole derivatives as somatostatin agonists or antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED INTELLECTUAL PROPERTY DEPARTMENT (JP) | 2006-10-05 | — | — | US | disclosed |
| EP-1562898-A1 | INDOLE DERIVATIVES AS SOMATOSTATIN AGONISTS OR ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2005-08-17 | — | — | EP | disclosed |
| US-20050148775-A1 | Process for production of heteroaryl-type boron compounds with iridium catalyst | MITSUBISHI RAYON CO., LTD. (JP) | 2005-07-07 | — | — | US | disclosed |
| EP-1481978-A1 | PROCESS FOR PRODUCTION OF HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST | Mitsubishi Rayon Co., Ltd. (JP) | 2004-12-01 | — | — | EP | disclosed |
| WO-2004046107-A1 | INDOLE DERIVATIVES AS SOMATOSTATIN AGONISTS OR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215828-A1 | Substituted indole derivatives | IDO1, IDO2, TPH1 | ALDH1A1 886/4885HSD17B10 1760/4885KDM4E 2535/4885 |
| US-20060223826-A1 | Indole derivatives as somatostatin agonists or antagonists | SSTR1, SSTR3, NPY1R | ALDH1A1 2632/4885HSD17B10 2328/4885KDM4E 2069/4885 |
| US-20100010224-A1 | PROCESS FOR PRODUCTION OF HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST | PIN4, IPO5, HLCS | ALDH1A1 3867/4885HSD17B10 2772/4885KDM4E 2745/4885 |
| US-20050148775-A1 | Process for production of heteroaryl-type boron compounds with iridium catalyst | PIN4, IPO5, HLCS | ALDH1A1 3867/4885HSD17B10 2772/4885KDM4E 2745/4885 |
| US-20190263819-A1 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | RET, HIPK4, HIPK3 | ALDH1A1 3254/4885HSD17B10 2507/4885KDM4E 937/4885 |
| US-10385026-B2 | Phthalazinones and isoquinolinones as rock inhibitors | MYLK, MYLK2, ROCK1 | ALDH1A1 2535/4885HSD17B10 1817/4885KDM4E 1119/4885 |
| US-10954241-B2 | Heterocyclic compounds as ret kinase inhibitors | RET, REL, BCR | ALDH1A1 3019/4885HSD17B10 2544/4885KDM4E 977/4885 |
| US-10844067-B2 | Heterocyclic compounds as RET kinase inhibitors | RET, HIPK4, HIPK3 | ALDH1A1 3254/4885HSD17B10 2507/4885KDM4E 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.